News

Axalimogene filolisbac is Advaxis’s investigational Lm Technology immunotherapy, while durvalumab is MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor. Around 66 patients will be included in the two-part, open-label Phase

TLRs are said to be important class of proteins that play a crucial role in the innate immune system and scientific evidence links aberrant TLR activation and signaling

The approval was based on data from the randomized, double-blind, multi-center Phase II BOLT study in patients with laBCC not amenable to local therapy or metastatic basal cell

Ibrance is an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, which are key regulators of the cell cycle that trigger cellular progression. With the validation

VL-2397 (ASP2397) is part of a potential new class of antifungal compounds for the treatment of systemic fungal infections, which are major causes of morbidity and mortality in

The first patient dosed is suffering from advanced adrenal cell carcinoma (ACC) and received a siRNA that blocks cell division. The company is focused on developing its proprietary

PD-1 inhibitor, also called a checkpoint inhibitor, works by exposing cancer cells to attack by the immune system by preventing the cancer cells from blocking an effective immune

Resunab is a new synthetic oral endocannabinoid-mimic drug that preferentially binds to a receptor called CB2 on immune cells and fibroblasts. According to several pre-clinical and ex-vivo models,

Currently, solithromycin is in Phase III development for the treatment of CABP and submission of a new drug application (NDA) is planned for 2016. The company is carrying